M. Nishimura (Sapporo, Japan), C. Vogelmeier (Marburg, Germany)
Anti-inflammatory effects of salmeterol/fluticasone propionate (SFC) on airway T-lymphocyte populations in COPD
Y. S. Qiu, P. Davis, J. Zhu, L. Peachey, N. C. Barnes, I. Pavord, M. Johnson, P. K. Jeffery (Leicester, Greenford, United Kingdom)
|  |
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in COPD: a placebo-controlled study of endobronchial biopsies
Y. S. Qiu, P. Davis, J. Zhu, L. Peachey, N. C. Barnes, I. Pavord, M. Johnson, P. K. Jeffery (Leicester, Greenford, United Kingdom)
| |
Inhaled corticosteroids and survival in patients with COPD receiving long-term home oxygen therapy
R. Tkacova, S. Toth, D. Sin (Kosice, Slovakia; Vancouver, Canada)
|  |
Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial
A. B. Choudhury, C. M. Dawson, H. E. Kilvington, S. Eldridge, W. Y. James, J. A. Wedzicha, G. S. Feder, C. J. Griffiths (London, United Kingdom)
| |
Effects of salmeterol/fluticasone propionate (SFC) on airway inflammation in induced sputum in COPD
I. Pavord, D. Parker, N. C. Barnes, M. Johnson, P. K. Jeffery (Leicester, Greenford, United Kingdom)
| |
Anti-inflammatory effects of salmeterol/fluticasone propionate (SFC) by smoking status in COPD
N. C. Barnes, Y. S. Qiu, J. Zhu, I. Pavord, M. Johnson, N. C. Thomson, P. K. Jeffery (Leicester, Greenford, United Kingdom)
| |
Roflumilast inhibited emphysema development in mice exposed to cigarette smoke
P. A. Martorana, R. Beume, M. Lucattelli, L. Wollin, G. Lungarella (Siena, Italy; Konstanz, Germany)
| |
Therapy optimization of alfa-1-antitrypsin deficiency based on a pharmacokinetic approach
C. de la Roza, D. Soy, B. Lara, C. Esquinas, S. Vila, A. Torres, M. Miravitlles (Barcelona, Spain)
| |